NovoSeven Wins Expanded Indication For Acquired Hemophilia
This article was originally published in The Pink Sheet Daily
Executive Summary
Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.
You may also be interested in...
Novo Drops NovoSeven Stroke Program Following Phase III Failure
Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.
Novo Drops NovoSeven Stroke Program Following Phase III Failure
Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.
FDA Should Relax Endpoint Requirements For Emergency Research, Novo Nordisk Says
“Reduction of substantial morbidity alone should be sufficient” benefit in medical trials conducted under emergency conditions, the firm says.